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Identifying chromosomal regions associated with glucocorticoid-regulated gene transcription 
Delsy Marina Martinez 
Abstract 
Glucocorticoid (GC) response elements (GREs) are genomic segments that confer GC-regulated 
transcription in by recruiting hormone-bound glucocorticoid receptor (GR) and nucleating assembly of 
transcriptional regulatory complexes (TRCs). The locations of GR binding, the functionality of those GR 
occupied regions (GORs) as GREs, and the molecular features and spatial organization that characterize 
active GREs are gene-, cell- and physiological-context specific, and poorly understood. Moreover, 
identification of the gene(s) targeted for regulation by a given GRE has been inferred by proximity, or 
examined outside the normal chromosomal context, rather than rigorously validated. We approached 
these two issues in two human cell lines with distinct tissue origins, treated or not with a hormonal ligand 
that activates GR. First, we took a systems approach to examine the GC response, cataloging GORs by 
ChIP-seq, comparing RNA-seq defined transcriptome datasets from three different laboratories, mapping 
short bidirectional transcripts by Pro-seq, and assessing higher order genome structure by in situ Hi-C. To 
identify a functional GRE, we focused on a single 1.4 Mb topological domain bearing a GC-regulated 
gene and multiple GORs, and used Cas9 mutagenesis for in-genome GOR editing, coupled with 
transcriptional analysis to assess GRE activity and identify target gene(s). Our work established an 
experimental and analytic workflow for identification of robust sets of GC-regulated genes, and for 
unequivocal determination and validation of GRE activity. We found some but not all of the GORs 
dispersed across the topological domain contributed to GRE activity, the GRE directly regulated only one 
or two of the seven genes within the domain, and that features such as bidirectional transcripts or 
chromosome looping were seen at some but not all functional GORs. These results are consistent with 
context-specific combinatorial assembly of TRCs into functional GREs, which together enable GCs to 
orchestrate organismal developmental and physiological actions comprised of gene- and cell-specific 
transcriptional regulatory events. 
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Chapter 1: Introduction 
 
Specific patterns of gene expression are required for developmental and physiological 
processes. Key players in this arrangement are genomic response elements, DNA segments that 
bind transcriptional regulatory factors (TFs) and nucleate assembly of multifactor transcriptional 
regulatory complexes (TRCs) to activate or repress target gene transcription. Advances in 
genomic technologies enable description of chromatin structure and putative response elements 
both at specific loci and genome-wide, but defining molecular determinants of their regulatory 
activities is greatly complicated by variation dependent on gene-, cell- and physiologic-context. 
Moreover, it appears that response element regulatory activities must be assessed in their normal 
chromosomal environments, suggesting that genome editing methodologies provide the only 
viable strategy for functional dissection, and for identification of cognate target genes. It seems 
likely that response element activities in each specific context may derive from unique 
combinations of bound factors and other molecular features, thus generating context-specific 
regulation. Thus, very few response elements and target genes have been unequivocally 
identified, despite commonplace assignment of genomic regions as enhancers based on proxy 
datasets (Halfon et al., 2019). By extension, the functions of bound factors and molecular 
features at a bona fide putative response element have not been established, and the gene(s) 
inferred to be regulated by putative response elements remain unknown.  
 
Several molecular features have been claimed to correlate with response element 
activities. Open chromatin, genomic regions highly accessible to nucleases, and presumably to 
TFs, have been described, commonly together with  particular histone modifications, such as 
H3K27Ac and H3K4me1 (Shlyueva et al., 2014). Other investigations cataloged TF binding 
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sequence (TFBS) motifs, or motifs for multiple different TFs tightly clustered in genomic 
segments (Yanez-Cuna et al., 2012; Meireles-Filho et al., 2009), and monitored their occupancy 
by corresponding TFs or by coregulatory factors recruited by them (Rogatsky et al., 2003; 
Weikum et al., 2017). More recently, short bidirectional transcripts, so-called eRNAs, have been 
mapped at candidate response elements (Halfon et al., 2019). 
 
In addition to these molecular features, at least two classes of higher-order genome 
structure have been suggested to be relevant. First, chromatin loops, up to 450 kb, that appear to 
bring into physical proximity certain promoters of regulated genes and putative response 
elements (Fraser et al. 2009, Bonev et al. 2016; Kaduake et al. 2009, Pombo et al. 2015); while 
spatial proximity is a tempting determinant of activity and target gene identity, direct studies 
have shown that it is not sufficient as an indicator of regulatory function (Shlyueva et al., 2014). 
Second, topologically associating domains (TADs), which are typically demarcated by bound 
Cohesin complex and CCCTC-binding protein (CTCF), and contain characteristic chromatin 
modifications and histone marks between these boundaries (Rao et al. 2014). Disruption of TAD 
boundaries can affect expression of nearby genes and promote disease states (Matharu et al., 
2015), and a common speculation is that TADs define interaction zones that constrain the range 
over which response elements can act. TAD boundaries appear to be generally conserved across 
several cell types and species (Rao et al., 2014). The domains are classified as euchromatin-like, 
compartment A, or heterochromatin-like, compartment B (Lieberman-Aiden et al. 2009), and are 
thought to enable intra- but not inter-domain looping interactions (Dixon et al., 2012). However, 
due to the lack of standard criteria for defining TAD boundaries, different researchers have 
assigned domains across a range from 40 kb to 3 Mb. 
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Although the molecular features and higher order structures described above comprise a 
provocative roster of correlates to putative response element function, the overarching problem is 
that response elements and their target genes have themselves not been functionally validated. 
Therefore, we have set out in this work to begin to define functional response elements and their 
target genes. Our approach is to focus on the actions of a single TF, the human glucocorticoid 
receptor (GR), the founding member of the nuclear hormone receptor family, and likely the best 
characterized metazoan TF. GR is constitutively expressed in virtually all vertebrate cells 
(Weikum et al., 2017), residing inactive in the cytoplasm until it binds a glucocorticoid (GC) 
ligand (such as cortisol, the natural human hormone or dexamethasone (dex), a synthetic GC 
drug), whereupon it translocates into the nucleus, binds to context-specific genomic GC response 
elements (GREs) (Chandler et al., 1983) and confers gene-, cell- and physiologic-context 
specific transcriptional regulation (Yamamoto et al., 1985, Yamamoto et al., 1998). 
 
Ligand-gating of GR activity allows candidate GREs and target genes to be inferred in 
comparative experiments carried out in the presence and absence of dex. For example: (i) GR 
ChIP-seq reveals thousands of genomic GR occupied regions (GORs) in ligand-treated cells 
(Reddy et al., 2009; Encode Consortium 2012); (ii) microarray analyses implies hundreds of 
genes either induced or repressed upon dex treatment, many of them cell-type specifically, in 
lung carcinoma (A549) versus osteosarcoma (U2OS) cells (Rogatsky et al. 2013). 
 
The context specificity of GR action has been discussed as a paradox in which this single 
TF controls a precise transcription program in a given setting, but displays facile plasticity, 
dramatically changing binding sites and target genes when the setting is altered (Weikum et al., 
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2017). A consequence is that GR action must be analyzed both at a systems level, e.g., to identify 
all genes regulated in a given context, and locus specifically, e.g., to describe the determinants 
and mechanism of action of an individual GRE. In the current work, we employ both approaches, 
describing whole genome approaches to defining TADs, chromosome loops, protein-coding and 
non-coding transcripts in presence and absence of dex, with an emphasis on definitive target 
gene identification; at the single locus level, we use genome editing procedures to unequivocally 
identify a functional GRE and to characterize its activities. 
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Chapter 2: Genome-wide analysis of GC response 
 
Introduction 
 
GR is expressed in virtually all vertebrate cells, but its actions are highly context specific, 
e.g., mediating immunosuppression and anti-inflammation in immune cells, modulating glucose 
and lipid metabolism in liver, reducing bone and muscle mass, driving lung maturation and 
surfactant biosynthesis, promoting cell proliferation in the dentate gyrus of the hippocampus. 
The implication is that a single DNA-binding TF, potentiated by a single hormonal ligand 
(cortisol in humans, or a synthetic homolog such as dex), is somehow controlling transcription of 
distinct batteries of genes in different cell contexts (Weikum et al., 2017). Thus, visualizing the 
spectrum of candidate GR-target genes and GREs in a given context could be achieved by 
various systems approaches that compare, for example, full transcriptomes and genomic 
structure from hormone treated and control cells.  
 
RNA-seq provides a sensitive quantitative strategy for monitoring transcription at the 
whole genome level. A typical experimental workflow involves RNA extraction, RNA 
fragmentation and reverse transcription, library construction and sequencing (Han et al., 2015). 
The computational and systems biology that follows depends upon the end goal, be it identifying 
new transcripts or alternative splicing analysis. RNA-seq has commonly been employed to 
measure differential expression, in which statistically significant differences in read counts are 
detected between two experimental conditions (Anjum et al., 2016). Unfortunately, however, 
agreement has not been achieved on a standard protocol, analysis pipeline and statistical metrics 
to identify differentially expressed genes (DEGs) or to infer biological relevance. The ENCODE 
Consortium established standards, guidelines and experimental practices for RNA-seq, e.g., 
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information to report for each sample, number of replicates and sequencing depth, but these 
guidelines have not been widely adopted, nor do they address the computational and system 
biology aspects. 
 
While procedural and computational differences are known to affect RNA-seq results (Li 
et al., 2014, T’Hoen et al., 2013, Khanin et al., 2013), it has not been generally considered 
whether statistical metrics for defining DEGs (e.g., log2FoldChange > 1) may exclude 
biologically relevant transcripts, or whether such tools should or should not be deployed prior to 
a systems biology step. Currently, the False Discovery Rate adjusted p (q) value<0.05 is a 
commonly used cutoff value for differential expression tests but is not guaranteed to be the first 
metric used to filter datasets. Instead, emphasis is placed on log2FoldChange values being 
greater than a user-specified threshold, but there is no a priori reason that a large 
log2FoldChange is more biologically relevant than a small log2FoldChange (Zarse et al., 2012).  
 
With these concerns in mind, we set out to compare RNA-seq data from dex-treated and 
control human A549 cells, collected in three different laboratories, but analyzed through the 
same computational pipeline, with the gene lists subjected to pathway analysis. We sought to 
establish and justify the use of metrics in a specified order that represents the biology of the 
glucocorticoid response in those cells. 
 
In addition to this transcriptome determination, we carried out two further systems 
analyses. First, we sought to map short, labile bidirectional transcripts, enhancer RNAs (eRNAs) 
or distal transcribed elements (dTREs), suggested to be selectively expressed at putative 
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response elements. Because eRNAs are not detected by standard RNA-seq, we collaborated with 
John Lis (Cornell University, Ithaca, NY) to perform Precision nuclear Run-On Sequencing 
(Pro-seq) in A549 and U2OS cells, with and without dex treatment. Pro-seq enables quantitative 
tracking of nascent transcripts genome-wide at nucleotide resolution (Wissink et al., 2019), 
which in turn identify distal transcribed elements.  
 
Finally, to provide a rational metric for defining the genomic segment searched for GREs 
that regulate a given target gene, we used in situ Hi-C to visualize the three-dimensional genome 
architecture in intact A549 and U2OS nuclei, inferring higher order chromatin structure, for 
which we suggest a standard criterion for demarcating TADs.  
 
Results & Discussion 
 
Identification of GR-regulated genes in one cell and physiologic context 
 
Description of RNA-seq datasets analyzed 
We examined three RNA-seq datasets produced by three laboratories from different 
research institutions (Figure 2.1; denoted as D1, D2, and D3). Each dataset consists of three 
biological replicates A549 cells treated with 100 nM dex or vehicle (EtOH) for 4 hrs. Each dataset 
sought to identify GC regulated genes—but acquisition of each entailed various pre-analysis (wet 
lab) differences (See Materials and Methods). Experimental factors that can affect differential 
expression analysis range from RNA extraction methods to sequencing depth, and can even be as 
seemingly trivial as the serum source, due to FBS-associated RNA contaminants (Wei et al., 2016).  
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Figure 2.1: Overview of experimental design of RNA-seq datasets from multiple 
laboratories. (A) Description of RNA-seq datasets of A549 cells treated with and without 100 
nM dex for 4 hours from 3 different laboratories. (B) Computational and systems biology 
pipeline devised for determination of differentially expressed genes that are glucocorticoid 
regulated. (C) Volcano plots. Red dots signify differentially expressed genes with q <0.01. 
FKBP5, a canonical glucocorticoid regulated gene, is present in all 3 datasets.  
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Several groups have probed sources of experimental variation extensively, such as mRNA 
(polyA+) enrichment (Zhao et al., 2018) and sequencing platform (Li et al. 2014). D1 used total 
RNA for cDNA synthesis but with a kit whose proprietary combination of enzymes allows for 
preferential priming of non-rRNA sequences and therefore a reduced number of reads from rRNA, 
whereas D2 and D3 isolated mRNA from total RNA. rRNA and tRNA make up >95% of total 
RNA and does not allow for efficient transcript/gene detection if not removed or biased against by 
selective priming. Poly(A) selection provides good recovery of mRNAs but biologically relevant 
RNA species lacking poly(A) go undetected. Hence, each RNA selection approach has advantages 
and disadvantages. All three datasets used the Illumina sequencing system, HiSeq. D3 doubled the 
amount of reads due to paired end (PE) sequencing, and D2, though single end (SE), used 100 bp 
read length; both approaches provided better alignment accuracy. 
 
Computational analysis pipeline  
We identified differentially expressed genes (DEGs) in each individual dataset with the 
pipeline outlined in Figure 2.1. We used HISAT2, a fast, efficient pipeline that employs splice 
junctions and hierarchical indexing for fast alignment to the hg38 human reference genome (Kim 
et al., 2015) rather than de novo transcriptome assembly, which was unnecessary in our case. 
Sequencing depth would further limit our ability to differentiate between transcripts/isoforms of 
genes for some of the datasets, therefore, we employed a gene-level summation using 
Featurecounts (Liao et al., 2013). This read summation process maps the number of reads to 
genomic features (e.g., exons) with a hg38 refFLAT GTF file containing chromosomal coordinates 
of exons and coding regions we provided along with the alignment file from HISAT2. Finally, we 
used DESeq2 (Love et al., 2014) to identify DEGs between vehicle- and dex-treated samples.  
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As a quality control measure, principal component analyses (PCA) of individual datasets 
revealed strong separation of vehicle and dex-treated samples across PC1, which provided the most 
variance. While each dataset identified GC-regulated genes, a PCA with the combined datasets 
displayed clustering based on dataset instead of treatment conditions as the primary source of 
variances (Figure 2.2). Sequencing read type and length conditions contributed to the variance as 
two of the three datasets displayed greater alignment due to PE sequencing or longer read lengths, 
which increased accuracy in alignment and therefore allocation of counts. Thus, combining 
samples from different datasets without accounting for variance across datasets is uninformative. 
When accounting for batch effects, the effect of treatment conditions by combining treated and 
vehicle samples from all of the datasets displayed 98% of all DEGs from the individual datasets. 
We developed an approach to infer “robust DEGs”, which are GC-responsive despite variance 
across the three datasets, using statistical metrics that probe biologically relevant pathways. 
 
Metrics for assessing robustness 
1. The False Discovery Rate adjusted q value is more appropriate than p value, given the 
need for multiple correction testing. A p value < 0.05 gives evidence against the null hypothesis, 
measuring the likelihood that a gene is significantly differentially expressed in the vehicle versus 
dex-treated samples. The q value is superior when dealing with thousands of genes, because it 
measures the likelihood of false positives; a q<0.05 threshold is a strong determinant of 
statistical significance. With a q<0.05, we identified 733, 1450, and 2115 differentially expressed 
genes in D1, D2, and D3, respectively (Figure 2.3). With a more stringent threshold of q<0.01, 
we lose 28% of regulated genes across all the datasets.  
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Figure 2.2: Combined PCA of RNA-seq datasets primarily differentiates individual datasets 
instead of treated versus untreated samples. (A) PC1 and PC2, which account for the majority 
of the variance, differentiate datasets whereas (B) PC3 and PC4 differentiate treatment. 
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Figure 2.3: Filtering list of differentially expressed genes for statistical significance and 
consistency. (A) Number of differentially expressed upregulated (gold) and downregulated 
(purple) genes with q<0.05. (B) Venn diagrams showcasing consistent genes from all 3 datasets 
with 503 genes with q<0.05 (left) and 367 genes with q<0.01 (right). 
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Consistent biological behavior across datasets and computational tools 
2a) An additional criterion for robustness was consistent biological behavior. A gene met 
this metric if it was statistically significant in all three datasets and was consistently upregulated 
or downregulated in all three datasets. With a q<0.05 we identified 503 genes versus 367 genes 
with q<0.01 that were consistently upregulated or downregulated in every dataset (Figure 2.3) 
(Table 2.1); no genes switched between dex-activation and -repression at q<0.05. The mean 
log2foldchange value of these robust DEGs was +0.3 at q<0.05, and +0.4 at q<0.01, which is 
equivalent to a greater than 1.23-fold change for differentially expressed genes in all datasets. The 
range of the mean log2FoldChange for these 503 genes is +6.87 to -3.48, which is equivalent to 
112-fold increase and 11-fold decrease in expression, respectively. DESeq2 by default finds an 
optimal value at which to filter low count genes. Unsurprisingly, genes that met the default low 
count filter but had low mean normalized counts in one or two of the datasets commonly had large 
deviations in mean log2FoldChange values. Examples of upregulated genes in all three datasets 
were TFCP2L1 and ACSL1, and consistently down-regulated genes included PLK2 and IER5, all 
of which align with known effects of GCs on lipid metabolism and stress response (D’Ippolito et 
al., 2018). 
      
2b) To determine biological relevance of thresholds, and justify cutoffs, we used 
QIAGEN’s web-based software application, Ingenuity Pathway Analysis (IPA, 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/). The manually 
curated content of the Ingenuity Knowledge Base efficiently determined the biological context of 
specific gene lists, and assessed effects of altering q values or log2foldchange values on pathway 
ranking and presence. IPA determines pathway significance with p<0.05 values reflecting the 
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likelihood of non-random overlap between inputs and pathways. D1 had 206 significant IPA 
pathways, with statistically significant DEGs at q<0.05. Interestingly, though D2 and D3 had 
more statistically significant DEGs at q<0.05 compared to D1, D2 and D3 had 194 and 197 
pathways, respectively, and they were neither complete subsets of each other nor of D1. Table 
2.2 compares the z-scores of pathways generated from genes with q<0.05 in individual datasets.  
 
Analyses of pathways generated from the robust gene list (Table 2.1) under different 
thresholds, q<0.05 and q<0.01, altered the p value ranking of pathways, but few pathways were 
gained or lost. The number of statistically significant pathways overlapped by greater than 80% 
regardless of q value threshold (Figure 2.4). The top ranking pathways were Glucocorticoid 
receptor signaling (p value=2.76E-07), Colorectal cancer metastasis signaling (p value=1.17E-06), 
NRF2-mediated oxidative stress response (p value=2.86E-06), IL-7 signaling (p value=6.69E-06) 
and p53 signaling (p value=7.96E-06 (Table 2.3). Acknowledging that IPA pathways containing 
more well-documented molecules, such as cancer pathways that are highly studied and reported, 
can skew the significance of dataset gene lists and pathway rankings, we were nevertheless pleased 
that GR signaling was top-ranked.  
 
2c) Another criterion for robustness involved using another parametric differential 
expression tool, EdgeR (Robinson et al., 2010, Liu et al., 2015), to compare the number of DEGs 
produced in the individual datasets with our set metric of q<0.05. EdgeR yielded >80% of the 
DEGs produced from DESeq2, which is a common range between the two different tools (Schurch 
et al., 2016). 
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Figure 2.4: Significant IPA pathways consistent with varying q values but massive 
differences observed with imposed log2FoldChange (L2FC) threshold. (A) Overlap of 
significant* pathways generated from robust differentially expressed genes with a q<0.05 (Grey) 
and q<0.01 (Pink). (B) Overlap of significant* pathways generated from robust differentially 
expressed genes with a q<0.05 (Grey) manually imposed log2FoldChange (L2FC) +1 (Dark 
Grey). *IPA determined p value in which p<0.05 reflects likelihood overlap between inputs and 
pathway are not random. 
 
  
16 
 
Importantly, the commonly used log2FoldChange >1 threshold is not a sound filter for 
biological relevance. Large fold changes do not guarantee biological relevance, while genes with 
small fold changes may be biologically relevant yet discarded. With our robust gene list at the 
q<0.05 threshold, we determined that a log2FoldChange+1 cutoff excluded 50% of genes and 
>60% of pathways (Figure 2.4). We could not confidently manually impose log2FoldChange 
filters because the biological processes, molecular functions and components generally remained 
consistent while varying q value thresholds but varied drastically when filtering with a stringent 
log2foldchange threshold. These biologically relevant pathways are derived from what is currently 
available in the literature by IPA and would take an additional effort to distinguish if the remaining 
pathways, when imposing log2foldchange thresholds, selected for essential pathways. The 
likelihood that a large log2foldchange selects for core pathways is contrary to published work 
showing genes not highly differentially expressed are biologically relevant (Zarse et al., 2012). 
Finally, it should be noted that RNA levels may not predict protein levels, as processes downstream 
of transcription may also be regulated (Vogel et al., 2012). 
 
Guidelines for DEG identification 
Based on our analysis of three RNA-seq datasets, we propose guidelines for metrics to 
identify robust DEGs: (1) filter by q value; (2) filter by consistent behavior; (3) allow the q value 
to determine the log2foldchange. We opted for a more inclusive q<0.05 value, as a 5% chance of 
a false positive seemed acceptable against the risk losing information at a more stringent threshold; 
notably, the pathway analysis using a q<0.01 setting overlapped strongly with that at the q<0.05 
setting. It is strongly advised to have at least 3 replicates for statistical validation of genes whose 
differential expression is reliable within a dataset. Our analysis of three datasets, which allowed 
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comparisons within and across datasets, captured >500 DEGs, with some genes unique to each 
dataset and some differences in pathway analysis; nevertheless, we found 503 consistent DEGs. 
Of course, it is not customary to compare RNA-seq datasets from different labs, but our analysis 
confirms that nonidentical results can emerge from slight differences in experimental and analytic 
approaches.  
 
In summary, we identified genes that were statistically significant based on a q value 
threshold of less than 0.05 or 0.01, which set a log2FoldChange cutoff to + 0.3-0.4 in each dataset. 
We further distinguished genes that were robust to experimental variation (library preparation, 
sequencing system, PE vs SE, and read length), as assessed by consistency in expression in all 3 
datasets. We ran these robust gene lists with varying q values and found that the IPA pathways 
were generally conserved. In contrast, imposing a stringent log2FoldChange threshold severely 
constrained the number of pathways with published findings linking them to the genes on our list. 
Therefore, the log2foldchange threshold is set by q value, rather than arbitrarily assigned.  
 
Bidirectional transcripts in response to GC exposure in two cell lineages 
We also looked at non-protein coding transcripts, as it has been claimed that short, 
bidirectional, noncoding transcripts from so-called distal transcribed regions (dTREs) are 
characteristic of functional response elements (hence, have been denoted as enhancer RNAs, 
eRNAs). We treated U2OS and A549 cells with ethanol, 1 nM, or 100 nM dex for 45 min, then 
performed PRO-seq (Erin Wissink, Cornell University). dTREs were identified using dREG 
(Wang et al., 2016) and differential expression was performed with DESeq2 (Love et al., 2014). 
We found that the overall dTRE landscape was A549- and U2OS-specific. PRO-seq identified 
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~63,175 constitutive dTREs in A549 cells and ~ 51,234 in U2OS cells (Figure 2.5). Intriguingly, 
a fraction of these dTREs (593 (0.9% of detected dTRE loci) in A549, 2,055 in (4% of detected 
dTRE loci) in U2OS are differentially responsive to GC signaling (100 nM dex relative to EtOH) 
at a p value ≤0.05 (in A549, log2FoldChange max = 8.1 [chrX:86,147,390-86,147,800], min = -
5.5 [chr10:100,696,430-100,696,959], median = 2.89, mean = 2.31 ± 2.88; in U2OS, 
log2FoldChange max = 7.2 [chrX:43,655,190-43,655,640], min = -5.1 [chr10:100,347,760-
100,348,300], median = 1.82, mean = 1.47 ± 2.14).  Further study is required to assess whether 
eRNAs play a role in GRE activity (See Chapter 3). 
 
 
 
 
Fig 5: Distal biredictional transcripts (dTREs) overlap with GORs distinctly in A549 and 
U2OS cell lines. 46% of A549 GORs overlap with dTREs whereas 26% of GORs overlap with 
dTREs in U2OS cells. 
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Human genome structure in response to GC exposure in two cell lineages 
To assess whether chromosome topological interactions (large-scale topological domains 
and/or smaller-scale intrachromosomal looping) may be related to or functional in GC 
regulation, we performed in situ Hi-C in both A549 and U2OS cell lines treated with 100 nM dex 
or EtOH vehicle for 1.5 hr. Hi-C relies on DNA proximity to produce genome-wide DNA-DNA 
contact maps.  
 
We first examined interchromosomal interactions between whole chromosomes in the 
human genome for either cell line. Heatmaps display the observed interactions between 
chromosomes relative to random expectations (Figure 2.6; clusters of red indicate preferential 
association between chromosomes whereas blue clusters indicate avoidance). As expected from 
prior reports (Lieberman-Aiden et al., 2009), gene-rich chromosomes preferentially associated 
with each other and to a lesser degree, gene-poor chromosomes also associated. We subtracted 
the dex- and vehicle-treated samples’ interaction frequencies for each chromosome after 
normalization by sequencing depth. The differences in the interaction frequencies did not favor 
association or avoidance between chromosomes, and dex treatment did not detectably alter 
chromosomal interactions.   
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Figure 2.6: Interchromosomal contacts do not appear or disappear with glucocorticoid 
treatment in A549 cells. Interchromosomal interactions in A549 cells treated with 100nM dex 
(left) or vehicle (right). Heatmaps of chromosome association where observed counts are 
normalized against random expectation and shown on log2 scale. Red indicates enrichment and 
blue indicates depletion of interactions.  A549 dex and EtOH interchromosomal heatmaps were 
normalized by valid read pairs and subtracted (bottom). 
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Intrachromosomal heatmaps display the same chromosomal region mapped to itself. 
Interactions on the diagonal are enriched, because these regions are close in three-dimensional 
space, whereas off-diagonal interactions represent long range interactions. At 100 kb resolution, 
dex did not provoke appearance or disappearance of putative TAD structures larger than 2 Mb 
encompassing GC-regulated genes in either A549 or U2OS, consistent with the previous 
observation of conservation of TAD boundaries and loops across several cell types and species 
(Rao et al., 2014). Figure 2.7, upper panels, display intrachromosomal Hi-C data in dex-treated 
and control A549 cells for a 10 Mb region of chromosome 10 in which each pixel is a 100-kb bin 
of the genome and a putative TAD is visible with the GC-regulated gene, ANKRD1 promoter at 
the TAD border. Figure 2.7, bottom panel, examines a 2 Mb segment of this region in the dex 
treated sample.  
 
We sought to use in situ Hi-C to assess in A549 and U2OS cells how a GC regulated 
gene may be influenced by DNA elements potentially within a TAD via chromatin loops. While 
we secured reproducible results, resolution was limited to 100kb, so we could not be confident 
that we were capturing chromatin loops that might bridge candidate GREs and cognate 
promoters, or even relatively small topological structures that might limit the search space for 
candidate response elements. For that reason, we relied on intrachromosomal Hi-C contacts at 
higher resolution (~5kb), in the A549 cell line provided by T. Reddy (Duke University). In the 
case of GC response, higher order genome structure appears to be ‘pre-wired’ in that chromatin 
loops detected before and after GC exposure are similar, albeit with some changes in interaction 
frequency (D’Ippolito et al., 2018). 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Putative TAD in A549 cells containing glucocorticoid regulated gene. 
Intrachromosomal interactions within 10 Mb region of chromosome 10 in A549 cells treated 
with 100nM dex (left) or vehicle (right) normalized by valid read pairs. Red indicates enrichment 
of interactions and every pixel corresponds to 100 kb region. Bottom box: Zoom in of putative 
~2 Mb TAD containing GC regulated gene, ANKRD1, in blue box at potential TAD border. 
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Figure 4: A549 Hi-C chromosome 10 contact profile.  
2 MB region at 100 kb resolution where more red 
corresponds to a greater intensity of  interactions.  
In blue is the ANKRD1 locus.  
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Material and Methods 
RNA-seq 
Experimental Biology 
For D1: 
Two T-225 flasks of A549 cell lines were maintained at 37 °C with 5% CO2 (v/v) in DMEM H-
16 low-glucose media supplemented with 5% (v/v) fetal bovine serum. Confluent cells were 
treated with 100nM dex (D4902-25MG) or EtOH-vehicle for 4 hr (old media was switched out for 
dex- or vehicle-containing media). RNA from 3x106 cells was purified using Qiagen RNeasy mini 
kit with QIAshredder columns and optional DNAse step with final elution in 50 L Ambion 
RNase-free water; eluants were snap frozen in liquid N2 and stored at -80°C. 15-25 ng total RNA 
was used to prepare amplified cDNA using Nugen’s Ovation RNAseq system V2 kit. 3 g cDNA 
was sheared with an S2 Focused-ultrasonicator (Covaris) set at intensity 5, duty cycle 10%, 
cycles/burst 200, and time = 60s for 2 cycles for fragment sizes ~100-400 bp. Libraries were 
constructed with 100ng in the Ovation Ultralow System V2 #1-16 (Part #0344) with 8 cycles 
amplification and quantified on a 2100 Bioanalyzer System (Agilent) with High Sensitivity DNA 
Kit. Each library was sequenced on a HiSeq 4000 (Illumina) using single reads of 50 bp in length.  
 
For D2: 
 
Refer to Pack, L.R., 2017:  
A549 cells were grown in 15 cm dishes using DMEM H-16 low glucose media supplemented 
with 5% (v/v) fetal bovine serum. Two 15 cm dishes were used for each condition analyzed by 
RNA-seq: i) Control siRNA/ethanol, ii) Control siRNA/dex. Pool of siRNA acting as a non-
targeting negative control (Darmacon, D-0018190- 10-20) were used for the reverse 
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transfections. 200 pmol of siRNA was diluted in 3.5 mL of Optimem-I media, followed by the 
addition of 42 µL of RNAiMAX (ThermoFisher) for each 15 cm plate. The mixtures were added 
to the 15 cm plates and incubated for 20 min at room temperature (rt). Following incubation, 
1.3x106 cells were plated in 16.5 mL of standard growth media. The cells were incubated with 
their respective siRNA pools for 72 hr after which the media was replaced with fresh media 
containing either 100 nM dex in 0.2% ethanol or 0.2 % ethanol for 4 hr. Following incubation 
with dex or ethanol, the media was removed and cells were collected by scraping with 1 mL of 
RLT buffer from the RNAeasy kit (Qiagen). RNA was isolated using Qiashredder and RNAeasy 
mini columns. RNA quantity was measured using Nanodrop spectroscopy, quality using the 
Bioanalyzer, and knockdown efficiency using qPCR. mRNA was isolated from total RNA using 
Oligotex mRNA isolation (Qiagen) as described in the protocol with two modifications: i) 
following the removal of supernatant from the Oligotex beads, water and OBB buffer were 
added and the heating, cooling and pelleting steps repeated; ii) beads were treated twice with 70 
µL of elution buffer. Following mRNA isolation, rRNA contamination was assessed using the 
Bioanalyzer . mRNA was precipitated with sodium acetate, isopropanol, and glycoblue and 
resuspended in 9 µL of 10 mM Tris pH7.0. To fragment the RNA, samples were heated to 95 °C 
for 2 min followed by 1 µL of fragmentation buffer (Ambion) and incubation at 95°C for 2 min; 
1 µL of stop solution was then added. Samples were run on a 10% TBU gel (Invitrogen) at 200 
V for 50 min. Gels were visualized by Sybr Gold and 80-120 bp RNA was cut from the gel. The 
RNA was gel extracted by first pulverizing the gel pieces and then incubating in 300 µL of 
DEPC water at 70 °C in a Thermomixer. Supernatant was collected through a SpinX column and 
precipitated with sodium acetate, ethanol, and glycoblue. Following precipitation, the RNA was 
resuspended in 7 µL of 10 mM Tris pH=7. 1 µL of 10x PNK buffer, 1 µL of Superase Inhibitor, 
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and 2 µL of PNK were added to each sample, which were then incubated at 37°C for 1 hr. 
Following incubation with PNK, linker ligation was achieved by adding 6 µL of PEG, 1 µL of 
linker-1, 1 µL of DTT, 1.1 µL of ligation buffer, and 1.5 µL of Truncated T4 RNA ligase 2 
(NEB M0242L). Linker ligation was performed for 2 hr at 37°C. Following ligations samples 
were precipitated and pellets were resuspended in 8.5 μL 10 mM Tris pH7.0 and run on a 10% 
TBU gel for 50 min at 200V. The ligated samples were cut from the gel and gel extracted as 
described. Following precipitation, samples were resuspended in 11 μL of 10 mM Tris pH7.0. 
0.8 μL of oCJ200 reverse transcription (RT) buffer was added to the ligated RNA and was 
incubated at 65°C for 5 min and 35°C for 5 min. Following incubation, 4 µL of 5x RT buffer, 1 
µL of DTT, 1 µL of dNTPs, 1 µL of Superase Inhibitor, and 1 µL of reverse transcriptase was 
added to the RNA primer mixture. Samples were incubated at 52°C for 12 min. Samples were 
then incubated with 2 µL NaOH for fifteen minutes at 95°C. After boiling, 2 µL of HCl was 
added to each sample to neutralize the pH. Samples were precipitated in Tris pH8.0, glycoblue, 
and ethanol, and run on a 10% TBU gel for 1 hr and 20 min at 200V. DNA was imaged and 
extracted. Samples were resuspended in 15 μL of 10 mM Tris pH8.0 and were circularized 
through the addition of 2 µL of 10x circ ligase buffer (epiBio), 1 µL of 20 mM ATP, 1 µL of 50 
mM MgCl2, and 1 µL of circ ligase (epiBio). Samples were incubated at 60°C for 1 hr and circ 
ligase was heat inactivated at 80°C for 10 min. After circularization, 3 µL of circ product was 
PCR amplified using Phusion. The PCR primers were primer 0231 and the indexed primers of 
interest. PCR conditions included an initial denaturation at 98°C for 30 sec followed by 10 or 12 
cycles of denaturation at 98°C for 10 sec, annealing at 60°C for 10 sec, and extension at 72°C for 
5 sec. Samples were run on a 8% TBE gel at 180V for 47 min. Amplified products were gel 
extracted. Following PCR amplification, the quality of the libraries was determined by 
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Bioanalyzer. Libraries were quantified by qPCR using the KAPA library quantification 
standards. We generated 5 nM solutions of each library and combined 2.5 μL of each sample for 
LRPA and LRPB. Samples were sequenced by the UCSF center for advanced technology on an 
Illumina Hi-seq using Rapid Run single reads of 100 bp in length. The sequencing primer used 
was oNTI202. Unpublished raw fastq files were provided by Lindsey Pack. 
 
For D3: 
Refer to links below for experimental procedures. Raw fastq files were downloaded from Encode.  
https://www.encodeproject.org/experiments/ENCSR632DQP/ 
https://www.encodeproject.org/experiments/ENCSR326PTW/ 
 
Computational Biology 
 RNA-seq profiling for three biological replicates from each of three datasets were performed 
and yielded ∼25–60 x106 mapped sequences. For quality control, mapping and read 
quantification, we employed the web-based platform Galaxy (usegalaxy.org). FastQC was used 
to evaluate the quality of reads (Andrew 2010). Raw Fastqs from each dataset were uniformly 
processed and analyzed, with the exception that Cutadapt (v1.16.3) was used for D2 to remove 
the 3’ sequence (CTGTAGGCACCATCAATATCTCGTATGCCGTCTTCTGCTTG) (Marcel 
2011). Reads were mapped using HISAT2 (v2.1.0+galaxy3) to the hg38 genome with default 
settings. We employed a gene-level summarization using Featurecounts (v1.6.3+galaxy2) with a 
hg38 refFLAT GTF file (UCSC Main on Human: refFLAT(genome)) containing chromosomal 
coordinates of exons and coding regions we provided along with the alignment file from 
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HISAT2 and default settings. Finally, we used R-DESeq2 (v1.22.2) to identify DEGs between 
vehicle (EtOH) and dex-treated samples in individual datasets. 
 
Systems Biology 
We submitted gene lists of individual datasets and robust gene list with q value thresholds <0.05 
or <0.01 through the Ingenuity Pathway Analysis (IPA) tool. We used the Core Analyses feature 
to obtain relevant relationships, mechanisms, functions and pathways for a given gene list. 
Pro-seq 
 
Cells were maintained in DMEM supplemented with FBS and pen/strep. 5 x106 cells were plated 
per experiment 24 hr prior to treatment. Media was supplemented with ethanol or the appropriate 
concentration of dex for 45 min and kept in a 37° C incubator with 5% CO2 during the 
incubation. Cells were kept on ice during the extraction protocol. Cells were washed with PBS, 
then incubated in PBS supplemented with 10 mM PBS for 5 min. Cells were scraped and placed 
in 15 mL Falcon tubes, then washed twice with PBS. Cells were then incubated in 
permeabilization buffer for 5 min, pelleted, and washed twice with permeabilization buffer. Cells 
were resuspended in freezing buffer and flash frozen. Run-on reactions with biotin-11-CTP and 
biotin-11-UTP were performed for 5 min. RNA was isolated, fragmented on ice with 0.2 N 
NaOH, and underwent buffer exchange with a P-30 column. Three biotin enrichments were 
performed with Dynabead streptavidin beads, and between enrichments, the 3' adapter was 
ligated, the 5' end was repaired with RppH and PNK enzymatic treatments, and the 5' adapter 
was ligated. RT was performed with SuperScript III, and 13 cycles of PCR were used to amplify 
the library, followed by clean-up with Ampure beads (1.6x ratio). 
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In Situ Hi-C 
Passage modified from Moquin et al., 2017: 
 
In situ Hi-C was performed with 5 x106 cells per experiment as described (Rao et al., 2014), with slight 
modifications. After end repair and washes, Dynabeads (Thermo Fisher Scientific) with bound DNA were 
resuspended in 10 mM Tris, 0.1 mM EDTA, pH 8.0, and transferred to new tubes. Sequencing libraries 
were created from bound DNA by using an Ovation Ultralow library system V2 kit (NuGEN), with one 
modification. After adapter ligation, because DNA was still attached to the beads, water instead of SPRI 
beads was added to the reaction mixture. Beads with bound DNA were purified by use of a magnet, 
washed, and resuspended in 10 mM Tris, 0.1 mM EDTA, pH 8.0. After library amplification, SPRI beads 
were added as directed to purify the amplified DNA. Quantitation and size distribution of libraries were 
performed using a Bioanalyzer High Sensitivity DNA kit (Agilent). Fifty-base PE reads were sequenced 
on a HiSeq instrument (Illumina). Once sequenced, PE reads were aligned to human reference genome by 
use of the Hi-C User Pipeline (HiCUP), version 0.5.0, using default parameters to generate a set of 
interactions. We used the human hg19 sequence. The HiCUP processing steps remove PCR duplicates as 
well as invalid read pairs, including those that are self-ligated or map to identical or adjacent fragments. 
Only alignments with mapq scores of ≥30 were retained. Data sets contained on average 25 x106 valid PE 
Hi-C contacts after quality control filtering. 
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Chapter 3: Identification of a glucocorticoid response element and a cognate target gene  
 
 
Introduction 
 
GR regulates gene networks that are precisely determined in a given context, yet displays 
remarkable plasticity as a function of cell type and physiological state. It accomplishes this feat 
by binding at context-specific genomic sites and provoking assembly of context-specific TRCs, 
which in turn modulate context-specific processes in mRNA production, such as initiation, 
release of stalled RNA polymerase II, elongation, splicing, etc. (Weikum et al., 2017). This 
extreme context specificity enables global regulators like GR to control organismal processes as 
aggregate outcomes of distinct effects in different cells and tissues, developmental stages and 
physiologic states. Context specificity also greatly complicates characterization and mechanistic 
analysis of response element activities, as there is no single set of molecular characteristics, no 
simple genomic map of functional GREs, no single mechanistic action that can be ascribed to 
functional GR. Rather, GREs are comprised of context-specific combinations of molecular 
features, higher order genomic arrangements and TRC components, which together modulate 
different steps in the transcription of cognate target genes. 
 
A consequence of this complexity is that systems approaches cannot identify functional 
response elements such as GREs. Most investigations have failed to appreciate this important 
point, and have used molecular features, higher order genomic organization and spatial proximity 
as surrogate criteria of response element function and activity. Candidate response elements have 
also been transferred onto plasmids and their actions measured on linked minimal promoter-
reporter gene constructs, despite clear evidence that native chromosomal context and target gene 
promoter context are critical determinants of response element function.  
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We conclude that at our present level of knowledge, functional response elements must 
be defined individually, and must be validated genetically in their normal chromosomal 
environment. Therefore, in this work, we interrogated our genome-wide datasets to select a gene 
that is GR-regulated in A549 and U2OS gene, and that resides in a well-resolved TAD bearing 
multiple GORs. We used CRISPR/Cas9-directed GOR ablation to define the functional GRE, 
combined with transcript analyses to identify the target gene(s).  
 
Results & Discussion 
GR occupancy on the human genome varies across cell lineages 
We mapped by ChIP-seq GR occupied regions (GORs) genome-wide in A549 and U2OS 
cells, treated with 100 nM dex or EtOH-vehicle for 1.5 hr. We observed 7, 313 GORs in A549, 
of which 67.4% are shared with U2OS and 24, 891 GORs in U2OS of which 19.8% are shared 
with A549; > 40 and >70% of the GORs summits encompassed a canonical GBS motif in A549 
and U2OS, respectively (Figure 3.1). Clearly, GORs are in substantial excess of GC regulated 
genes (Figure 3.2). 
 
We focused on a TAD defined by Hi-C contacts occurring within a 1.4 Mb region of 
chromosome 10 that is conserved across several cell types, including A549 (Figure 3.3). The 
TAD encompasses 7 coding genes. Only ANKRD1 is GC responsive in A549, with the nearest 
GC responsive gene is more than 2 Mb away and outside of the TAD. In contrast, in U2OS, 
ANKRD1and HECTD2 are dex-responsive within the TAD. ANKRD1 resides near one boundary, 
and HECTD2 is near the center of the TAD. Interestingly, ANKRD1 is upregulated in A549 cells 
at 100 nM dex, whereas in U2OS, ANKRD1 is activated at 1 nM but repressed at 100 nM dex; 
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HECTD2 is activated at both dex concentrations in U2OS. The TAD includes 4 and 15 GORs in 
A549 and U2OS, respectively; all 4 A549 GORs coincide with U2OS GORs. 
 
 
 
 
 
 
Figure 3.1: GOR overview in A549 and U2OS cells. (A) Overlapping and distinct GR 
occupancy in A549 (orange) and U2OS (blue) cell lines. (B) Number of loci with GBS 
intersecting with one (1) or fifteen (2) bp of GOR summit versus random 1 or 15 bp region 
(grey). (C) Enrichment of GBS motif matches across 1 kb zones centered on GOR peak summit 
(Heatmap color scale ranges from green to blue to pink (most significant)). 
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Figure 3.2: Gene, GOR and TAD overview in chromosome 10. Example overview of 
topological units (purple), genes (all vs dex-responsive (blue = downregulated, red= 
upregulated), GORs in A549 and U2OS cells. 
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Figure 3.3: 1.4 Mb topological unit with distinct GOR occupancy and GC gene regulation 
in A549 and U2OS cells. GORs numbered left to right in 1.4 Mb region on chromosome 10 in 
A549 (orange) and U2OS (blue) cells with some overlapping (4, 6, 8, 12) and unique ChIP-seq 
peaks. Genes within TAD are boxed in red. ANKRD1 is GC responsive in both A549 and U2OS 
cells and HECTD2 is responsive only in U2OS cells. Hi-C contacts in grey not extending past 
housekeeping genes, RPP30 and BTAF1, serve as the demarcation of TAD. 
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Cas9 mutagenesis of GR occupancy at single loci 
 
We used directed Cas9 genome editing to generate chromosomal deletions or insertions 
(indels) that disrupt GBS motifs, or GOR peak summits for GORs lacking a GBS. A GOR 
regulating ANKRD1 was discovered by a homozygous, ~120 bp deletion of GOR4. GOR4 is 
slightly upstream of the ANKRD1 promoter (-0.451 kb) and contains a single GBS. In A549, a 
single H3K27Ac site was disrupted by deletion of GOR4 (Figure 3.4), and dex induction of 
ANKRD1 declined by 75% (Figure 3.5). In U2OS, ANKRD1 is no longer upregulated at 1 nM and 
further downregulated at 100 nM with loss of GOR4 (Figure 3.6).  
 
We examined the GOR4 region in the A549 wild type and GOR4 mutant by ChIP-seq, and 
confirmed the loss of the GOR4 peak (Figure 3.4). In A549, ANKRD1 expression in the absence 
of dex was elevated by 2.5-fold in the GOR4 mutant, implying that non-GR TF or chromatin 
remodeling binding sites may have been deleted or created by the ~120bp GOR4 deletion. RNA-
seq established that only ANKRD1 transcription levels were changed significantly by the GOR4 
mutant, examining the surrounding ±1 Mb region, either in the absence (Table 3.1) or the presence 
(Table 3.2) of dex. Genome-wide, dex-regulated expression of four additional genes, none residing 
on chromosome 10, appeared to be altered in the GOR4 mutant (Table 3.3). Further testing is 
required to validate these findings, and to test whether dex regulation of those genes is primary, 
i.e., controlled directly by GR, or secondary. Our provisional conclusion is that GOR4 displays 
GRE activity that is nearly fully specific to ANKRD1 in A549. Interestingly, this appears to 
contrast with a report in which a Cas9-driven deletion of a single H3K27Ac locus in HCT116 
colon cancer cells produced large scale changes in gene expression of several genes ±1 Mb from 
the deletion (Tak et al., 2016). 
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Figure 3.4: Validation of GOR4 deletion in A549 cells. A549 wildtype (WT, purple) sequence 
containing one GBS highlighted in red. A549 GRE mutant (MT) is a homozygous 120 basepair 
deletion which ablates GBS and GOR4 upstream of ANKRD1 that overlaps with H3K27Ac mark 
(green). 
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Figure 3.5: ANKRD1 induced and basal expression is affected by deletion of GOR4 in A549 
cells. RNA-seq and qPCR show a 4-fold decrease in ANKRD1 expression when comparing 
wildtype (WT) and mutant (MT) levels (left) and 2.5-fold increase in ANKRD1 expression in 
mutant when compared to wildtype basal levels (right). 
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Figure 3.6: Multiple GORs affect expression of single GC regulated gene, ANKRD1.  
(A) Zoom in on chromosome 10 topological unit focusing on GOR1 (+135kb) downstream of 
ANKRD1 and GOR4 (-0.451kb) upstream of ANKRD1. (B) ANKRD1 regulatory analysis of 
GOR1 (+135kb) and GOR4 (-0.451kb) ablations across 0.01, 1, and 100 nM dex dose. 
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GRE composition 
We have found that multiple GORs can influence transcription of a single GC-responsive 
gene (Figure 3.6). Interestingly, mutation of GOR4 (-0.451kb) in U2OS abrogated ANKRD1 
upregulation at 1 nM, but strengthened its downregulation at 100 nM, whereas mutation of 
GOR1 (+135kb) abrogated its downregulation at 100 nM. Hence, it appears that GR regulates 
expression in ANKRD1, at least in U2OS, from a composite GRE that includes at least two 
GORs separated by >135kb. It will be very interesting to interrogate the other GORs within this 
TAD. We speculate that control by dispersed composite GREs will prove to be common, 
whereas some GORs in the TAD will lack detectable activity in the two contexts assessed here, 
but may well be highly functional in other contexts. 
 
 Finally, we note that thousands of GORs overlap with intergenic or intronic regions that 
produce dTREs in each cell line (Figure 2.5). GOR1 overlaps with 1 dTRE in U2OS cells 
whereas GOR4 does not display dTREs, but genome-wide, 26% and 46% of GORs overlap with 
dTREs in U2OS and A549 cells, respectively. We detected 37 dTREs within the TAD; 1 
overlapped with GOR6 in A549 versus 5 overlapping with GORs 1, 5, 6, 7, and 9 in U2OS cells. 
Of the 37 dTREs, only 1 dTRE had expression affected significantly (p<0.05) by dex in A549 
cells and it did not overlap with a GOR. In U2OS, only 1 dTRE had expression affected 
significantly by dex and it overlapped with GOR6. While a role for dTREs/eRNAs in GRE 
activity remains to be investigated, it would be consistent with the context specificity of response 
element composition and function to assume that dTREs will be found at some but not all GORs, 
and at some but not all GREs. 
 
  
39 
 
Materials and Methods 
 
GR ChIP-seq 
A549 and U2OS.hGR cells were grown in ~3 T-225 cm flasks to 90% confluency. After 90 min 
treatment with dex (Sigma) at 100 nM or ethanol (Koptec), cells were harvested by 
trypsinization, counted on a hemocytometer, and distributed to 50-mL Falcon tubes in volumes 
corresponding to ~1.8 x 107 cells/tube (anticipating ~1.8 x 107 cells/ChIP). 36.5% formaldehyde 
was added to suspended cells to a final concentration of 1% v/v; after incubating 3-10 min at RT, 
formaldehyde was quenched by adding 2.5 M glycine to 0.3 M, RT 5 min, followed by transfer 
to ice. Cells were recovered by centrifugation at 450g, 5 min, 4 ˚C, then washed twice by 
resuspension and pelleting in 20 mL ice-cold TBS (100 mM Tris-HCl, pH 7.5 @ 4 ˚C/150 mM 
NaCl) on ice. Cells were then washed 3x at RT in 1 mL MC lysis buffer (10 mM Tris-HCl, pH 
7.5 @ RT, 10 mM NaCl, 3 mM MgCl2, 0.5% (v/v) Tergitol type NP-40), resuspended in 1 mL 
RT MC lysis buffer and transferred to a 1.5 mL Eppendorf tube. Cells were pelleted at 200g, 5 
min; residual buffer was removed and cells were frozen in liquid N2 for storage at -80 ˚C. 
Frozen nuclear pellets were thawed in cool water, resuspended in 180 µL MNase reaction buffer 
(10 mM Tris-HCl, pH 7.5 at RT, 10 mM NaCl, 3 mM MgCl2, 1 mM CaCl2, 4% (v/v) Tergitol 
type NP-40) supplemented with PMSF to 1:100, and the volume was taken to 270 µL with 
MNase reaction buffer. MNase (New England Biolabs) was diluted 1:10 in MNase reaction 
buffer, and 1.35 µL was added to the resuspended chromatin and incubated at 37 ˚C, 5 min. A 
cOmplete Mini, EDTA-free Protease Inhibitor Cocktail tablet (Roche) was dissolved in 500 µL 
MNase buffer (PIn cocktail); MNase reaction was stopped by adding 5.4 µL 0.2 M EGTA (pH 
8), 7.2 µL 100 mM PMSF, 14.65 µL PIn cocktail, 14.65 µL 20% SDS, and 14.4 µL 5 M NaCl, 
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with gentle tube inversion to mix. 164 µL volume was transferred to each of two 1.5 mL 
Bioruptor®Plus TPX microtubes (Diagenode, Denville, NJ) and sonicated in a Bioruptor® Plus 
(UCD-300) Sonication System using intensity setting ‘H’ (320 W) and sonication parameters 
“CYCLE Num:30, Time ON:30sec, Time OFF:30sec”. During a 15-min rest interval, samples 
were vortexed for 5 sec, spun down in a microfuge, and transferred to new TPX tubes on ice, 
followed by a second round of sonication (amounting to 60 cycles total). 150 µL Dynabeads™ 
Protein G slurry (Invitrogen) was mixed with 20 mg N499 (rabbit α-human GR IgG) antibody 
plus 450 µL Lysis Buffer 2 (10 mM Tris-HCl, 1 mM EDTA, 150 mM NaCl, 5% (v/v) glycerol, 
0.1% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1% (v/v) Triton X-100, pH 8 at 4 ˚C; no PIn 
added) in a 1.5 mL Eppendorf tube, incubated 1 hr with rolling in 4 ˚C cold room; tubes were 
placed in magnetic rack and supernatant was removed. Sonicated chromatin samples were 
pelleted at maximum speed, 10 min, 4 ˚C, and white pellet and cloudy suspension above pellet 
were recovered by transferring from 1.5 µL TPX tubes to new 1.5 mL tubes. 10 µL aliquot of 
combined input was set aside for later processing. 25 µL 100X Halt™ Protease Inhibitor 
Cocktail (Thermo Scientific) was added to a 5 mL tube with 2.5 mL Dilution Buffer (identical to 
Lysis Buffer 2, except without SDS). ~275 µL chromatin (from ~1.5 x 107 cells) was added to 
the Dilution Buffer+beads in the 5 mL tube, effectively diluting the chromatin 1:10. The 5 mL 
tube was sealed with parafilm and incubated 4 h on a roller in a 4 ˚C cold room. During this time, 
input material was reverse-crosslinked by adding TE (10 mM Tris-HCl, 1 mM EDTA, pH 8; pH 
7.5 at RT) to a total volume of 80 µL, followed by addition of 100 µL ChIP Elution Buffer (50 
mM Tris-HCl, pH 7.5 @ RT, 10 mM EDTA, 1% SDS) and 20 µL Pronase (Roche, 20 mg/mL) 
for incubation at 42 ˚C for 2 hr, then 65 ˚C overnight. 100X Halt PIn was warmed to RT, and 15 
µL was added to 1.5 mL of each of three Wash Buffers (A-C; Wash Buffer A: Buffer A 
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containing 10 mM Tris-HCl, 1 mM EDTA, 150 mMNaCl, 5% (v/v) glycerol, 0.1% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 1% (v/v) Triton X-100, pH 8.0; Wash Buffer B: Buffer A with 
500 mM NaCl and Halt protease inhibitor mixture; Wash Buffer C: 20 mM Tris-HCl, 1 
mM EDTA, 250 mM LiCl, 0.5% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, Halt 
protease inhibitor mixture, pH 8.0 ). Beads were washed consecutively in 1.5 mL of each of the 
Wash Buffers A-C (1X Halt PIn), by gently adding buffer to resuspend the beads, then placing 
the tube on a magnetic rack and removing the supernatant after beads settled. Chromatin (from 
1.5 x 107 cells on beads from 150 µL slurry) was eluted from beads in 300 µL Elution 
Buffer/Reverse-Crosslinking Buffer (10 mM Tris-HCl, 1 mM EDTA, 0.7% (w/v) SDS, pH 8 at 
RT) by incubating beads in buffer for 5 min, RT with gentle pipetting to occasionally mix, then 
allowing beads to settle on magnetic rack and transferring eluant volume to a new 1.5 mL 
Eppendorf tube. To reverse crosslinks, 450 µL Adjustment Buffer (50 mM Tris, 10 mM EDTA, 
0.45% SDS pH 7.0 at RT) was added with 82.5 µL Pronase (20 mg/mL) to 300 µL eluted 
chromatin, followed by incubation at 42 ˚C for 2 hr, then 65 ˚C overnight. DNA was 
subsequently cleaned from “input/MNase only” samples using a Qiagen PCR Purification Kit, 
and MinElute PCR Purification Kit (Qiagen) columns were used to purify ChIPs (one 
column/each ChIP, using 2.5 mL ERC buffer or 4.16 mL PB buffer), eluted in 15 µL EB. 
Recovered DNA was stored at -20 ˚C. Libraries were generated using an Ovation® Ultralow 
System V2-32 (NuGEN Technologies, Redwood City, CA), quantified on a 2100 Bioanalyzer 
System (Agilent, Santa Clara, CA) with High Sensitivity DNA Kit. Each library was sequenced 
on a HiSeq (Illumina) using single reads of 50 bp in length. Bigwig files were generated using 
the MACS2 callpeak algorithm in Galaxy (usegalaxy.org), and displayed as a custom track in the 
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UCSC Genome Browser (http://genome.ucsc.edu) with files hosted at Cyverse Discovery 
Environment (https://de.cyverse.org/de/). 
GBS selection 
ANKRD1 ENSG00000148677 TSS was defined as CAGE peak at chr10:90,921,087 in hg38 
(GRCh38/hg38 human genome assembly, accession GCA_000001405.15), FANTOM5 CAGE 
phase 1&2 pooled human tracks (fantom.org). A549 and U2OS.hGR GR occupied regions called 
by MACS2 in a 1.4 Mb vicinity of ANKRD1 TSS (GRCh38/hg38 chr10:90,756,900-92,156,900) 
were selected for functional analysis, with GOR identifier designated based on approximate 
below-summit GBS position relative to TSS. 500-1000 bp regions were recovered from the 
UCSC Genome Browser using ‘Get DNA’ function and populated into SnapGene.dna files for 
archiving and analysis. Putative direct DNA-binding motifs recognized by GR at peak summits 
were identified by scanning DNA files for a degenerate GBS ‘match’ (‘extremely generic GBS 
motif’ 5’-NNNACANNNNGTNCNN-3’) and by analysis in rsat matrix-scan 
(http://rsat01.biologie.ens.fr/rsat/matrix-scan_form.cgi) using the TRANSFAC NR3C1 
positional weight matrix with markov order 1 and p value upper threshold 5e-2 (0.05).  
 
GBS/GOR editing 
Single guide (sg) RNAs that deliver S. pyogenes Cas9 to genomic target loci were identified 
using two publicly available SpCas9 sgRNA design tools, sgRNA Designer 
(https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design) and CRISPR-MIT 
(crispr.mit.edu): for 250-bp regions flanking a GR ChIP-seq peak-centered GBS or GR ChIP-seq 
peak summit (i.e., GOR), guide selections identified in sgRNA Designer were cross-referenced 
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to guides identified in CRISPR-MIT in MySQL. sgRNA sequences were populated as ‘primers’ 
in SnapGene sequence files and prioritized for selection based on targeting within or near GBS 
motifs, high on-target efficacy scores and high efficiency scores. For Cas9 RNPs, sgRNAs were 
synthesized as T7 RNA Pol in vitro transcription (IVT) products from a double-stranded DNA 
template. dsDNA template was synthesized by PCR using 4 primers in multiplex: 18-mer 
ML557 (TAA TAC GAC TCA CTA TAG), 22-mer ML558 (AAA AGC ACC GAC TCG GTG 
C), 93-mer ML611 (AAA AGC ACC GAC TCG GTG CCA CTT TTT CAA GTT GAT AAC 
GGA CTA GCC TTA TTT AAA CTT GCT ATG CTG TTT CCA GCA TAG CTC TTA AAC) 
and target-specific 58-mer comprising 5’ 18-mer (5’-TAATACGACTCACTATAG-3’) and 3’ 
20-mer (5’-GTTTAAGAGCTATGCTGGAA-3’). 100-µL PCRs were performed as follows: 20-
µL 5X Phusion buffer (125 mM TAPS-HCL, 250 mM KCl, 10 mM MgCl2, 5 mM 
βmercaptoethanol), 2 µL 10 mM dNTPs, 8 µL ML557+558 at 12.5 µM each, 0.5 µL ML711 at 4 
µM, 0.5 µL target-specific oligo at 4 µM, 1 µL Phusion pol, cycled using thermocycler program 
IVT_TMPL (95 ˚C 30 sec, 95 ˚C 15 sec, 57 ˚C 15 sec, 72 ˚C 15 sec (cycle to step 2 30x), 72 ˚C 
30 sec, 10 ˚C indefinitely. PCR products was isolated using DNA Clean & Concentrator-5 kit 
(Zymo) and eluted in 12 µL nuclease-free H2O. IVTs were performed in 100 µL reaction 
volumes with 5X reaction buffer (components), 2 µL each NTP (each at 25 mM), 5 µL 100 mM 
DTT, 600-700 ng template DNA (10 µL PCR product), incubated 4 h–o/n, 37 ˚C. RNA was 
isolated using RNA Clean & Concentrator-5 columns (Zymo), eluted in 15 µL nuclease-free 
H2O; RNA concentration was estimated in a NanoDrop™ Microvolume Spectrophotometer 
(ThermoFisher) and diluted as appropriate for sgRNA stock ~100 µM (estimating that sgRNA 
MW ~37 kDa, 3700 ng/µL ~100 µM). sgRNAs were assembled with Cas9-NLS protein (QB3 
MacroLab, Berkeley, CA; qb3.berkeley.edu/macrolab/) as follows: for single RNP 
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nucleofections, sgRNA volumes corresponding to 40-100 pmol sgRNA were distributed to 500 
µL non-stick, nuclease-free Eppendorf tubes (Ambion) on ice; 40 pmol Cas9-NLS (1 µL Cas9-
NLS at 40 µM/6.4 mg/mL in 20 mM HEPES-KOH, pH 7.5, 150 mM KCl, 10% glycerol, 1 mM 
DTT; Mw 160.95 kDa) was added, then 50 pmol carrier DNA (0.5 µL Alt-R Cas9 
electroporation enhancer nucleic acid at 100 µM, IDT); the resulting ~2.5 µL volume was 
incubated at 37 C for 15 min, transferred to ice; 10- 11 µL cells suspended in buffer R at a 
concentration of 2.5 x 106 cells/mL were then added directly to the RNP volume, for a final 
concentration of ~1.6 pmol/µL RNP (~1.6 µM RNP in cell suspension, ratio of ~108 RNP 
molecules per cell). 10 µL RNP+cell suspension was transferred into 10 µL Neon tip and 
nucleofected into A549 and U2OS.GR populations using the Neon™ Transfection System 
(ThermoScientific) with 10 µL Neon tips, and the following electroporation settings (pulse 
voltage (V), pulse width (ms), pulse #: A549: 1200, 30, 2; U2OS.GR: 1200, 10, 4). Nucleofected 
cells were delivered to 12-well or 6-well dishes containing pre-warmed DMEM/high glucose 
(HyClone)/10% FBS (GemCell) for recovery, and incubated for 24 – 72 h before FACS isolation 
of individual cells.  
 
Clonal isolation by FACS 
Single cells were delivered to 100 μL HAM’S F-12 media (Lonza, Basel, Switzerland), (A549) 
or DMEM/5% FBS mixed 1:1 with conditioned media (U2OS.hGR) in individual wells of 96-
well plates (Corning, Kennebunk, ME) by FACSAria2 (BD Biosciences, San Jose, CA) in the 
UCSF Center for Advanced Technology, and grown for 3-4 weeks with regular media 
replacement after 2 weeks. Media in 96-well plates was changed by aspiration using 8-channel 
adapter (Argos Technologies, Elgin, IL; EV503) attached directly to aspirator tubing and fitted 
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with sterile, disposable pipet tips (Rainin SS-L10); all processing for media addition was 
performed using sterile filter tips.  
 
Allele description (genotyping)—Cells were prepared for genotyping by removing media, 
washing with 100 μL DPBS/Modified (–calcium/–magnesium) (HyClone Laboratories, Logan, 
UT), and trypsinization with 30 μL 0.5% trypsin-EDTA (Gibco/ThermoScientific, Waltham, 
MA). 15-20 μL volume from each trypsinized well was transferred to corresponding well of 96-
well, 0.2 mL/well TempPlate semi-skirted polypropylene PCR plate (USA Scientific, Ocala, FL) 
for lysis, and 100 μL fresh media was added to remaining cells in 96-well plate for return to 
culture. Cells in polypropylene plates were sealed with cold storage foil (USA Scientific), lysed 
by adding 15 μL 2X lysis buffer+1:100 Recombinant PCR Grade Proteinase K (Roche, Basel, 
Switzerland), with thermocycler incubation at 65 °C 30 min., 95 °C 15 min. Amplicons were 
prepared for massively parallel sequencing in two PCR reactions, performed in Hard-Shell® 
PCR plates, 384-well, thin-wall (Bio-Rad Laboratories, Hercules, CA): PCR1 (~219 bp 
amplicons)—4 μL lysate in 20 μL PCR volume, TCHDWN: cycled at 98 °C 2 min 30 sec, [98 
°C 30 sec, 57-62 °C 20 sec, 72 °C 30 sec (30x)], 72 °C 8 min. PCR2 (~302-bp amplicons)—0.5 
μL PCR1 template in 20 μL volume, with i5 and i7 indexed primers at 200 nM. SampleSheet 
preparation for Illumina MiSeq (Illumina, San Diego, CA) was automated for barcoded 
amplicons using SampleSheet.py (Ehmsen et al., in preparation, 
https://github.com/YamamotoLabUCSF). Following PCR2, 5 μL from each well was pooled, 
100 μL pooled amplicons were column-cleaned (Zymo DNA Clean & Concentrator-5, Genesee 
Scientific, San Diego, CA), concentration was estimated by NanoDrop (ThermoFisher 
Scientific), and library was quantified using the KAPA Library Quantification Kit for Illumina 
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platforms at 2-3 concentrations (serially diluted to 1,000,000 – 100,000,000-fold dilutions to 
reach within commercial standards, according to manufacturer’s instructions and quantification 
template (www.kapabiosystems.com). Sequencing was performed using MiSeq Reagent Kit v2 
(300-cycles) or MiSeq Reagent Nano Kit v2 (300-cycles) according to manufacturer’s 
instructions, at 8 – 12 pM (typically 10 pM) library with φX DNA (Illumina PhiX Control v3) at 
5-30% (typically 5%). Data were monitored in Illumina BaseSpace (basespace.illumina.com), 
fastq files were directly transferred from the MiSeq instrument to an external drive for 
processing, and processed in bash for Mac OS to identify top reads per well. Top reads were 
aligned to a reference sequence in SnapGene 4.0.8 (GSL Biotech LLC, Chicago, IL; 
www.snapgene.com) using Tools⟶Align Multiple Sequences, to assess alleles and genotypes in 
clones. Target clones were expanded from 96-well plates to 48- or 12-well plates, 6-well plates, 
and finally to 100-mm plates, by trypsinization, etc., from which three vials were frozen in 
DMEM/5% FBS/5% DMSO in styrofoam blocks or Mr. Frosty freezing containers (Thermo 
Scientific) and archived for long-term storage in liquid N2.  
 
Regulatory analysis by qPCR 
3 mL cells at 1.2 – 1.5 x 105 cells/mL were plated in 6-well dishes. 24 – 36 h later, media was 
removed and replaced with 2.4 mL media with charcoal-stripped FBS (Omega Scientific, 
Tarzana, CA). 3 h later, 600 μL media containing 5X dex (Sigma Scientific, St. Louis, MO) was 
added. 4 hr later, media was aspirated, cells were rinsed with 3 mL PBS, and following 
aspiration, cells were lysed in situ with 350 μL RLT buffer (1:100 β-mercaptoethanol). Cell 
lysate was transferred to 1.5 mL Eppendorf tubes, flash-frozen in liquid N2, and stored at -80 °C. 
RNA was isolated by RNEasy (Qiagen, Hilden, Germany) according to manufacturer 
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instructions, with DNase treatment (50 μL RNase-free DNase (Qiagen)), eluted in 30 μL 
nucleasefree H2O. RNA concentration was determined by NanoDrop. cDNA was synthesized in 
20-μL volumes with 1 μg RNA template, 4 μL 5X iScript reaction mix, 1 μL iScript reverse 
transcriptase, incubated under ISCRIPT thermocycler program in RNase-free 0.5-mL microfuge 
tubes (Ambion) (25 °C 5 min, 42 °C 30 min, 85 °C 5 min, 4 °C indefinitely). RNA stocks were 
stored at -80 °C after flash-freezing; cDNA reaction products were stored at -20 °C. cDNA 
reactions were diluted 4-fold, with 4 μL/reaction (50 ng/reaction). 6 μL primers at 0.83 μM 
(each) were added; 20 uL final qPCR reaction volume, the final working concentration of each 
oligo will be 250 nM. Add 10 μL SsoAdvanced Supermix low-retention tips and multichannel 
pipet if possible, 95 °C 30 sec, 95 °C 5 sec, 57 °C 30 sec, (cycle to step 2 39x). Note plate types, 
Microseal ‘B’ optically clear adhesive seals (Bio-Rad). Note primer IDs. qPCR primer pairs 
were designed using IDT PrimerSelect tool and selected for assay use based on certification for 
between-cycle 2-fold amplification efficiency across a 7-sample, 10-fold serial dilution of cDNA 
(maximum 50 ng cDNA tested, 2-fold amplification efficiency accepted up to empirical cutoff of 
Cq = 33, beyond which linearity abruptly declines) and target specificity as monitored by qPCR 
melt curve analysis. Primers mixed as pairs (667 nM in H2O) and cDNA (50 ng/ μL) were 
prepared in separate wells of 384- well source plates (Labcyte) and delivered to 384-well white 
PCR plates (Bio-Rad) at 3000 nL and 1000 nL/well, respectively, using an Echo® 525 Acoustic 
Liquid Handler (Labcyte Inc., San Jose, CA). 4000 nL SsoAdvanced Supermix (BioRad) was 
then added from 6-well reservoir source plate (final assay concentrations: 50 ng cDNA/reaction, 
250 nM/primer, 8 μL reaction volume). Plates were sealed with Microseal ‘B’ optically clear 
adhesive seals (Bio-Rad), centrifuged 5 min. at 1500g, and processed for qPCR at 95 °C 30 sec, 
95 °C 5 sec, 57 °C 30 sec, (cycle to step 2 39x), with endpoint melt curve analysis. RNA only 
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(no RT) controls were processed in parallel for every primer pair and cDNA sample, certifying 
qPCR signal attributable to amplification from cDNA template.  
 
Locus evaluation (topological unit/TAD designation) 
Metazoan genomes are increasingly recognized to exhibit intrachromosomal looping or nested 
sets of heightened interaction/proximity frequencies at distances ranging from several kb to 
hundreds of kb; although many long-range proximities may be incidental (without evolutionarily 
selected function), others may participate in regulatory control of specific genes or gene hubs.  It 
is presently difficult to define stable borders between sub-chromosomal regions in which 
unexpectedly high proximity interactions can be detected by chromosomal conformation assays; 
we chose to bin TADs (topological units) based on publicly available 5-kb resolution HiC data 
(Reddy lab, Duke University, Chapel Hill, NC).  Topological domains were defined based on 
publicly available HiC datasets (D’Ippolito et al. 2018), rendered as tabix files hosted at Cyverse 
Discovery Environment for viewing in the UCSC Genome Browser. Briefly, we converted 
HICCUPS file contact data for 5-kb genomic units to tabix files (Li et al., 2011); then using 
custom Python code, we populated chromosome-length lists with binary (‘0’ vs. ‘1’) definitions 
for each bp, with ‘0’ denoting no evidence of that bp partaking in long-range interaction with 
another bp block, and ‘1’ denoting HiC evidence for that bp partaking in a long-range interaction 
with another bp block.  The resulting Python lists were processed in pandas data frames to mark 
chromosomal units that either comprised topological interactions or were void of topological 
interactions, thereby fractionating the genome into topological units.  We mapped genes, GORs, 
and dTREs into these units based on bedtools intersects.  HiC contact heat maps were 
additionally visualized in cloud-based Juicebox (www.aidenlab.org/juicebox/). 
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Appendix to Chapter 3 
 
Once GREs are functionally identified, we aspire to identify the protein components of 
the TRCs at those loci. We have begun to develop and validate a new technology, 
CasCUT&RUN (Matthew Knuesel, UCSF), which will enable for the first time isolation and 
purification of in vivo assembled, GRE-specific TRCs. Ultra-high resolution mass spectrometry 
will then be used to identify resident proteins and their post-translational modifications. 
 
Results 
Chromatin fragment recovery from CUT&RUN 
In preliminary studies, we have validated CUT&RUN (Skene et al., 2017) as the basis for 
modification to CasCUT&RUN. DNA fragments of the appropriate size were solubilized from 
digitonin-permeabilized, Concanavalin-A bead immobilized cells, and incubated with control or 
H3K27Me3-antibody followed by ProteinA-MNase (Appendix Figure 3.1). These validated 
procedures serve as the basis for development of CasCUT&RUN. 
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Appendix Figure 3.1: Validation of CUT&RUN for use in CasCUT&RUN. CUT&RUN 
schematic from Skene et al., 2017 (left) and Bioanalyzer trace of ProteinA-MNase cleaved and 
solubilized DNA from 42,000 cells incubated with anti-H3K27Me3 or pre-immune IgG control 
antibody (right). CasCUT&RUN approach overview (bottom).  
CUT&RUN
Skene and Henikoff
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Chapter 4: Discussion 
 
 
Jacob and Monod (1961) established that prokaryotic transcription is regulated by a TF 
bound adjacent to a target gene promoter and affecting RNA polymerase function. However, this 
concept seems insufficient to account for transcriptional regulation in metazoans, where genes 
are expressed with remarkable cell- and physiological-context specificity. Britten and Davidson 
introduced the idea of combinatorial regulation (1969), which in principle could enable context 
specificity if metazoan TFs were dynamic multifactor TRCs assembled as context-specific 
combinations of broadly expressed TFs and co-regulators. 
 
Our lab showed that GR, which regulates distinct gene networks in different cell-and 
physiological contexts, receives and integrates multiple signals (e.g., hormonal ligands, DNA 
binding sequences, post-translational modifications, interacting non-GR TFs) as allosteric 
effectors that together drive distinct GR conformations bearing specific patterns of interaction 
surfaces for association with particular co-regulator factors, such as histone modification 
enzymes and chromatin remodeling machines, etc. Hence, context-specific signaling to GR 
results in context-specific TRC assembly, in turn conferring context-specific regulatory functions 
on GR, which alone is merely a DNA-binding scaffold protein lacking intrinsic transcriptional 
regulatory activity (Weikum et al., 2017).  
 
Context-specific combinatoriality introduces enormous complexity into identification and 
validation of GRE or any response element, as there is no simple “GRE code” that specifies 
DNA binding sites, TRC components, genome features or higher order organization, or even a 
regulatory action or mechanism, that corresponds to a functional GRE. Thus, systems analyses 
52 
 
cannot identify GREs, and instead, they must be validated individually using genome editing 
procedures that allow genetic analysis in normal chromosomal context. Similarly, the capacity of 
metazoan transcriptional regulation to operate over long range, vastly greater and more flexible 
than the base-pair positional specificity of prokaryotic response elements relative to their target 
gene promotors, complicates identification of cognate target gene(s) for a given GRE, from 
amongst all candidate GC-regulated genes, identified by whole genome systems approaches such 
as RNA-seq.  
 
Decades ago, our lab demonstrated sequence-specific binding by GR, showed that a DNA 
fragment bearing GR-binding sequences could confer GC regulation on a remotely positioned 
heterologous promoter, and denoted that first functional response element as a GRE (Chandler et 
al.,1983).  Since that time, progress in securing a full understanding of the defining properties 
and mechanisms for response element actions, and in unequivocal identification of target genes, 
has been severely hampered by failure to acknowledge and address context specificity. Instead, 
numerous reports have appeared describing systems analyses that catalog features whose 
relationships to response element activity rely on untested assumptions and/or flawed assays, 
together with inference of target gene identity based virtually solely on linear or topologic 
proximity.  
 
Clearly, neither systems nor reductionist approaches alone can predict response elements 
or provide insight into allostery-determined combinatorial regulation of transcription. In the 
present work, we have established for the first time a standard for unequivocal identification of 
functional response elements and cognate target genes, and a path forward for determination of 
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TRC composition and mechanism. Context specificity demands that GREs be characterized and 
validated individually, using first genetic, and eventually molecular and biochemical approaches. 
Target genes can then be imputed by assessing the effects of GRE mutations on genome-wide 
GC-regulated transcription.  
 
In time, with CRISPR mutagenesis of candidate GREs and genetic screens like Perturb-
seq, it should be possible to probe functionality of GORs and apply machine learning algorithms 
to high throughput studies such as RNA-seq, HiC, and Pro-seq, to divulge classes of response 
elements. With validated response elements and cognate target genes in hand, we will be able to 
determine whether chromatin loops are essential GRE properties, linking GORs to each other or 
to a target gene promoter; we could assess whether topological unit demarcation functions to 
constrain GRE activity to that domain; we could test whether eRNAs are functional components 
of GREs. With successful development of CasCut&Run, we could define the outcome of context 
specificity, identifying the composition of TRCs that are the products of signal-driven allostery. 
In summary, functional validation of response elements and their cognate target genes, as we 
have described here, is an essential first step to derive mechanistic insights into context-specific 
metazoan transcriptional regulation; our work with GR can be generalized to other eukaryotic 
TFs and response elements. 
 
When numerous GRE-target gene combinations have been defined, we predict that 
subsets of GREs that control a given physiologic property, e.g., GC-mediated 
immunosuppression, will be found to bear nonidentical but overlapping features and 
characteristics. This potential to assign GREs to functional and compositional sub-classes could 
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open a pathway to design and screen new therapeutics for treatment of diseases and pathologic 
conditions influenced by glucocorticoids.  
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Table 2.1 Robust differentially expressed genes that are glucocorticoid regulated derived 
from 3 different RNA-seq datasets filtered by q<0.05 and consistency. 
 
Geneid D1_MNC D2_MNC D3_MNC ML2FC PSE 
ZBTB16 11 18 20 6.87 2.27 
IP6K3 10 55 57 6.75 1.81 
KLF15 4 76 47 6.36 2.15 
BEST2 4 18 86 6.16 2.26 
EDN3 17 23 343 6.11 1.84 
STAC2 42 273 329 5.31 0.92 
TGFBR1 2403 4088 27848 1.19 0.23 
ITGA5 576 2511 4722 1.18 0.26 
TNS4 7983 8041 9636 1.18 0.21 
FAM222B 1301 1802 2481 1.17 0.21 
NAV2 1065 1614 2554 1.16 0.29 
MTSS1L 637 5209 2317 1.16 0.23 
NOL3 109 1131 695 1.16 0.32 
CHST7 144 1141 1780 1.13 0.30 
RAP1GAP2 124 594 1896 1.12 0.37 
SNX8 212 3816 2355 1.12 0.27 
 
 
MNC= Mean Normalized Counts 
ML2FC= Mean log2FoldChange 
PSE= Propagated Standard Error 
 
For full table refer to Supplemental material. 
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Table 2.2. Significant IPA pathways with z-scores* generated when comparing significant 
genes (q<0.05) from individual RNA-seq datasets.  
 
Canonical Pathways D1  D2  D3  
1D-myo-inositol Hexakisphosphate Biosynthesis II (Mammalian) 2.643906 1.73539 1.619185 
Actin Cytoskeleton Signaling 2.462857 1.388326 2.490645 
Adipogenesis pathway 2.389909 4.292143 3.97629 
Aldosterone Signaling in Epithelial Cells 3.280751 4.532621 3.182586 
AMPK Signaling 3.562997 1.883844 1.919056 
Apelin Cardiac Fibroblast Signaling Pathway 2.309694 1.377331 1.966831 
Aryl Hydrocarbon Receptor Signaling 1.777732 1.806659 3.614807 
Axonal Guidance Signaling 2.212286 5.505336 4.364587 
B Cell Receptor Signaling 6.486534 3.255869 4.843051 
cAMP-mediated signaling 3.374472 3.561877 2.012879 
Cardiac Hypertrophy Signaling 2.268857 3.021608 2.223682 
CD27 Signaling in Lymphocytes 2.160571 3.754794 5.436833 
CD40 Signaling 2.934406 2.281777 5.615934 
Cholecystokinin/Gastrin-mediated Signaling 3.767673 3.744966 4.40559 
Coagulation System 2.304078 1.965551 2.890629 
Colorectal Cancer Metastasis Signaling 6.071404 7.828613 5.269203 
D-myo-inositol (1,3,4)-trisphosphate Biosynthesis 2.643906 1.73539 1.619185 
Death Receptor Signaling 3.705599 4.21389 2.242668 
Dopamine-DARPP32 Feedback in cAMP Signaling 2.615848 3.561038 1.527505 
Endocannabinoid Cancer Inhibition Pathway 3.732522 5.906265 2.617165 
Ephrin A Signaling 1.309416 2.523677 1.385245 
ERK/MAPK Signaling 5.500968 3.146976 2.251855 
Erythropoietin Signaling 2.129856 2.316979 2.026099 
FAT10 Cancer Signaling Pathway 3.205523 2.173376 4.68403 
G-Protein Coupled Receptor Signaling 6.271612 4.242412 4.272729 
Germ Cell-Sertoli Cell Junction Signaling 2.249039 5.426497 5.492191 
Glioblastoma Multiforme Signaling 1.65853 4.34853 1.938122 
Glucocorticoid Receptor Signaling 6.975216 2.997772 3.726176 
GNRH Signaling 3.897797 3.598599 3.725523 
Gα12/13 Signaling 2.638167 2.693414 2.757247 
Gαq Signaling 4.1459 2.909962 2.849026 
Hepatic Cholestasis 3.672366 1.789902 4.591475 
HER-2 Signaling in Breast Cancer 1.911651 2.306768 2.126638 
HGF Signaling 2.240166 5.133435 3.667105 
HIPPO signaling 2.785495 5.395457 1.740107 
HMGB1 Signaling 4.891232 1.568172 2.82961 
Human Embryonic Stem Cell Pluripotency 2.587956 3.309917 1.981469 
IGF-1 Signaling 2.977284 2.613001 2.290066 
IL-15 Signaling 2.821795 1.441507 2.185325 
IL-17 Signaling 2.515274 2.452659 4.169711 
IL-17A Signaling in Fibroblasts 1.597324 2.516619 6.070165 
IL-6 Signaling 5.092213 3.372676 4.838371 
IL-7 Signaling Pathway 5.062841 2.852634 3.640857 
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Canonical Pathways D1  D2  D3  
IL-8 Signaling 5.534844 2.878552 5.281046 
ILK Signaling 3.17568 2.536524 4.294798 
Integrin Signaling 3.98307 3.168003 1.875243 
JAK/Stat Signaling 3.790389 2.965972 3.753987 
Leukocyte Extravasation Signaling 2.03031 2.301522 2.348736 
Molecular Mechanisms of Cancer 5.307066 5.63485 4.325399 
Mouse Embryonic Stem Cell Pluripotency 1.508663 2.940608 1.885225 
Neuregulin Signaling 5.062841 2.452659 2.676043 
NF-κB Signaling 5.555803 2.589104 3.873892 
NRF2-mediated Oxidative Stress Response 5.603326 5.03428 4.930995 
Osteoarthritis Pathway 7.043288 9.387797 8.868343 
p53 Signaling 4.788103 4.264839 5.68214 
p70S6K Signaling 2.247157 2.821382 2.866489 
Pancreatic Adenocarcinoma Signaling 4.409603 1.905684 2.749329 
PEDF Signaling 2.452856 3.602853 3.53153 
Phospholipase C Signaling 3.430408 1.510878 1.662007 
PI3K Signaling in B Lymphocytes 2.365433 3.422913 3.058173 
PI3K/AKT Signaling 4.750667 4.597864 3.305299 
PPARα/RXRα Activation 5.591886 2.06237 3.518141 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 2.754767 2.865988 3.542982 
Prolactin Signaling 2.044714 2.17237 2.767532 
Protein Kinase A Signaling 6.552419 6.728815 4.192154 
PTEN Signaling 5.666282 2.182808 2.710541 
Pyridoxal 5'-phosphate Salvage Pathway 2.955853 3.812655 3.728923 
RANK Signaling in Osteoclasts 3.280535 3.489395 4.584293 
Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes 2.749788 2.418637 2.540031 
Regulation of the Epithelial-Mesenchymal Transition Pathway 4.142112 4.153821 3.892539 
Role of IL-17A in Arthritis 2.142947 2.475979 5.228995 
Role of IL-17F in Allergic Inflammatory Airway Diseases 2.51678 1.347999 2.74813 
Role of JAK2 in Hormone-like Cytokine Signaling 3.169118 2.610244 2.319303 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 7.704222 10.22705 7.500913 
Role of NFAT in Cardiac Hypertrophy 2.964131 4.263755 2.621085 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 4.586137 6.058212 3.692843 
Role of Tissue Factor in Cancer 3.466248 1.316639 1.696787 
Salvage Pathways of Pyrimidine Ribonucleotides 2.392311 2.260049 2.502588 
Semaphorin Signaling in Neurons 2.160571 1.34905 1.751605 
Signaling by Rho Family GTPases 2.464832 1.7461 3.506808 
STAT3 Pathway 3.466248 1.316639 5.058376 
Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism 2.237757 2.503949 1.88316 
Superpathway of Inositol Phosphate Compounds 3.589532 2.905062 2.061907 
Tec Kinase Signaling 4.403678 1.727516 1.358031 
Thrombin Signaling 2.447693 1.857448 1.825301 
TNFR2 Signaling 2.604299 3.731476 5.946274 
Type II Diabetes Mellitus Signaling 5.569767 4.350193 3.499235 
VDR/RXR Activation 3.708659 4.896869 4.007937 
VEGF Signaling 4.229428 3.095633 1.98179 
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Canonical Pathways D1  D2  D3  
Wnt/β-catenin Signaling 3.333721 6.831619 4.49353 
Xenobiotic Metabolism Signaling 1.761764 1.937908 2.578716 
Adipogenesis pathway 2.389909 4.292143 3.97629 
Induction of Apoptosis by HIV1 1.870271 1.726929 1.849297 
Adrenomedullin signaling pathway 2.525959 1.965462 1.914548 
Apoptosis Signaling 2.98057 4.48977 1.742702 
April Mediated Signaling 2.843392 1.686666 3.927846 
B Cell Activating Factor Signaling 2.7277 1.564348 3.731838 
Circadian Rhythm Signaling 3.241586 1.605227 2.395433 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis 2.157214 1.482325 1.400982 
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 2.157214 1.482325 1.400982 
Factors Promoting Cardiogenesis in Vertebrates 1.539124 2.503278 1.511383 
GADD45 Signaling 1.659524 2.297122 1.538295 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 3.946922 1.346507 5.203837 
IL-1 Signaling 2.579651 1.819164 2.323672 
iNOS Signaling 3.26515 1.347999 4.059563 
NF-κB Activation by Viruses 3.015909 1.358075 1.422867 
LPS-stimulated MAPK Signaling 2.452856 1.358075 2.164607 
p38 MAPK Signaling 2.823452 1.462723 2.116711 
Phagosome Formation 4.032202 1.316639 1.696787 
Phosphatidylethanolamine Biosynthesis II 1.494239 1.396366 1.796522 
PPAR Signaling 2.811401 2.082144 2.340891 
RhoA Signaling 1.744632 2.182808 1.622267 
Role of PKR in Interferon Induction and Antiviral Response 2.009216 1.564348 3.0521 
Small Cell Lung Cancer Signaling 3.31868 1.335007 3.992418 
T Cell Exhaustion Signaling Pathway 2.628443 1.440375 1.652109 
Toll-like Receptor Signaling 5.276365 2.144276 4.143018 
TWEAK Signaling 3.099294 1.965551 5.19109 
Wnt/Ca+ pathway 1.837685 2.523677 1.385245 
Type I Diabetes Mellitus Signaling 2.014714 1.693589 2.774934 
 
*z-score is a statistical measure of the match between expected relationship direction and 
observed gene expression. A z-score > 2 or < -2 is considered significant. Note that the actual z-
score is weighted by the underlying findings, the relationship bias, and dataset bias. 
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Table 2.3 Canonical IPA pathways from robust gene list with log(p-values). 
 
Ingenuity Canonical Pathways -log(p-value) 
Glucocorticoid Receptor Signaling 6.56E+00 
Colorectal Cancer Metastasis Signaling 5.93E+00 
NRF2-mediated Oxidative Stress Response 5.54E+00 
IL-7 Signaling Pathway 5.17E+00 
p53 Signaling 5.10E+00 
Molecular Mechanisms of Cancer 5.05E+00 
Protein Kinase A Signaling 4.96E+00 
G-Protein Coupled Receptor Signaling 4.70E+00 
Insulin Receptor Signaling 4.61E+00 
Aldosterone Signaling in Epithelial Cells 4.45E+00 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 4.41E+00 
Neuregulin Signaling 4.39E+00 
B Cell Receptor Signaling 3.94E+00 
ErbB Signaling 3.91E+00 
Wnt/β-catenin Signaling 3.90E+00 
Integrin Signaling 3.88E+00 
Cholecystokinin/Gastrin-mediated Signaling 3.87E+00 
PI3K/AKT Signaling 3.84E+00 
Phagosome Formation 3.76E+00 
VEGF Signaling 3.74E+00 
ERK/MAPK Signaling 3.69E+00 
Osteoarthritis Pathway 3.56E+00 
p70S6K Signaling 3.53E+00 
HMGB1 Signaling 3.51E+00 
VDR/RXR Activation 3.48E+00 
Paxillin Signaling 3.44E+00 
Human Embryonic Stem Cell Pluripotency 3.40E+00 
PTEN Signaling 3.38E+00 
Tec Kinase Signaling 3.35E+00 
Regulation of the Epithelial-Mesenchymal Transition Pathway 3.33E+00 
Role of NFAT in Cardiac Hypertrophy 3.26E+00 
cAMP-mediated signaling 3.24E+00 
Pyridoxal 5'-phosphate Salvage Pathway 3.24E+00 
Type II Diabetes Mellitus Signaling 3.16E+00 
Circadian Rhythm Signaling 3.13E+00 
T Cell Exhaustion Signaling Pathway 3.11E+00 
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Ingenuity Canonical Pathways -log(p-value) 
Macropinocytosis Signaling 3.09E+00 
Endocannabinoid Cancer Inhibition Pathway 3.09E+00 
Adipogenesis pathway 3.09E+00 
Role of JAK2 in Hormone-like Cytokine Signaling 3.07E+00 
Superpathway of Inositol Phosphate Compounds 3.06E+00 
IGF-1 Signaling 3.03E+00 
JAK/Stat Signaling 3.03E+00 
PPARα/RXRα Activation 3.03E+00 
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 2.97E+00 
HER-2 Signaling in Breast Cancer 2.88E+00 
Salvage Pathways of Pyrimidine Ribonucleotides 2.85E+00 
Glioblastoma Multiforme Signaling 2.83E+00 
ILK Signaling 2.81E+00 
Neuroinflammation Signaling Pathway 2.75E+00 
IL-8 Signaling 2.69E+00 
SPINK1 General Cancer Pathway 2.64E+00 
Germ Cell-Sertoli Cell Junction Signaling 2.63E+00 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 2.63E+00 
HIPPO signaling 2.55E+00 
NF-κB Signaling 2.51E+00 
Gαq Signaling 2.47E+00 
FAT10 Cancer Signaling Pathway 2.47E+00 
Cell Cycle: G1/S Checkpoint Regulation 2.44E+00 
IL-3 Signaling 2.41E+00 
Prolactin Signaling 2.39E+00 
Nitric Oxide Signaling in the Cardiovascular System 2.39E+00 
Factors Promoting Cardiogenesis in Vertebrates 2.36E+00 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 2.35E+00 
IL-17 Signaling 2.34E+00 
Gα12/13 Signaling 2.33E+00 
Virus Entry via Endocytic Pathways 2.32E+00 
Caveolar-mediated Endocytosis Signaling 2.31E+00 
IL-4 Signaling 2.26E+00 
HGF Signaling 2.25E+00 
Actin Cytoskeleton Signaling 2.25E+00 
Pancreatic Adenocarcinoma Signaling 2.23E+00 
PDGF Signaling 2.21E+00 
Toll-like Receptor Signaling 2.17E+00 
69 
 
Ingenuity Canonical Pathways -log(p-value) 
1D-myo-inositol Hexakisphosphate Biosynthesis II (Mammalian) 2.16E+00 
D-myo-inositol (1,3,4)-trisphosphate Biosynthesis 2.16E+00 
Coagulation System 2.14E+00 
Apelin Endothelial Signaling Pathway 2.13E+00 
Thrombin Signaling 2.12E+00 
Glioma Invasiveness Signaling 2.11E+00 
GADD45 Signaling 2.09E+00 
Axonal Guidance Signaling 2.09E+00 
Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency 2.07E+00 
Phospholipase C Signaling 2.07E+00 
ErbB4 Signaling 2.06E+00 
FAK Signaling 2.01E+00 
PI3K Signaling in B Lymphocytes 1.98E+00 
Dopamine-DARPP32 Feedback in cAMP Signaling 1.97E+00 
Huntington's Disease Signaling 1.97E+00 
Signaling by Rho Family GTPases 1.97E+00 
IL-15 Signaling 1.96E+00 
IL-6 Signaling 1.96E+00 
Ephrin A Signaling 1.92E+00 
Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes 1.92E+00 
Apelin Cardiac Fibroblast Signaling Pathway 1.91E+00 
14-3-3-mediated Signaling 1.91E+00 
Inositol Pyrophosphates Biosynthesis 1.90E+00 
Small Cell Lung Cancer Signaling 1.89E+00 
Regulation of Cellular Mechanics by Calpain Protease 1.89E+00 
Chronic Myeloid Leukemia Signaling 1.89E+00 
Erythropoietin Signaling 1.87E+00 
Mouse Embryonic Stem Cell Pluripotency 1.87E+00 
Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism 1.86E+00 
Sirtuin Signaling Pathway 1.86E+00 
CXCR4 Signaling 1.83E+00 
eNOS Signaling 1.80E+00 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 1.78E+00 
TGF-β Signaling 1.76E+00 
Ephrin Receptor Signaling 1.76E+00 
mTOR Signaling 1.74E+00 
Epithelial Adherens Junction Signaling 1.74E+00 
Lymphotoxin β Receptor Signaling 1.74E+00 
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Ingenuity Canonical Pathways -log(p-value) 
ERK5 Signaling 1.74E+00 
Clathrin-mediated Endocytosis Signaling 1.73E+00 
LPS-stimulated MAPK Signaling 1.72E+00 
NF-κB Activation by Viruses 1.72E+00 
Antiproliferative Role of TOB in T Cell Signaling 1.72E+00 
Ovarian Cancer Signaling 1.71E+00 
EGF Signaling 1.71E+00 
Cardiac Hypertrophy Signaling 1.71E+00 
VEGF Family Ligand-Receptor Interactions 1.70E+00 
Leukocyte Extravasation Signaling 1.68E+00 
Thrombopoietin Signaling 1.66E+00 
Glutamine Biosynthesis I 1.65E+00 
Sphingosine-1-phosphate Signaling 1.65E+00 
Fc Epsilon RI Signaling 1.64E+00 
TR/RXR Activation 1.62E+00 
Th1 and Th2 Activation Pathway 1.62E+00 
AMPK Signaling 1.61E+00 
Natural Killer Cell Signaling 1.59E+00 
Renin-Angiotensin Signaling 1.59E+00 
RAR Activation 1.58E+00 
Hepatic Cholestasis 1.58E+00 
Role of Tissue Factor in Cancer 1.56E+00 
STAT3 Pathway 1.56E+00 
Pregnenolone Biosynthesis 1.55E+00 
ErbB2-ErbB3 Signaling 1.55E+00 
RANK Signaling in Osteoclasts 1.55E+00 
TNFR2 Signaling 1.55E+00 
Semaphorin Signaling in Neurons 1.53E+00 
Docosahexaenoic Acid (DHA) Signaling 1.50E+00 
Androgen Signaling 1.49E+00 
Th1 Pathway 1.48E+00 
CD40 Signaling 1.47E+00 
Xenobiotic Metabolism Signaling 1.45E+00 
GNRH Signaling 1.44E+00 
3-phosphoinositide Biosynthesis 1.44E+00 
SAPK/JNK Signaling 1.41E+00 
Amyotrophic Lateral Sclerosis Signaling 1.40E+00 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis 1.38E+00 
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Ingenuity Canonical Pathways -log(p-value) 
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 1.38E+00 
Apelin Pancreas Signaling Pathway 1.38E+00 
TWEAK Signaling 1.38E+00 
Angiopoietin Signaling 1.37E+00 
Histidine Degradation VI 1.37E+00 
Acute Phase Response Signaling 1.37E+00 
Gap Junction Signaling 1.37E+00 
Glutamine Degradation I 1.36E+00 
Neuropathic Pain Signaling In Dorsal Horn Neurons 1.34E+00 
Induction of Apoptosis by HIV1 1.34E+00 
IL-12 Signaling and Production in Macrophages 1.33E+00 
p38 MAPK Signaling 1.32E+00 
Actin Nucleation by ARP-WASP Complex 1.31E+00 
G Beta Gamma Signaling 1.31E+00 
Telomerase Signaling 1.31E+00 
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TABLE 3.1 
Basal expression changes of genes +/- 1 Mb from GRE deletion on chromosome 10. 
Gene Coordinates log2Fold Change q-value 
LOC101926942 92,162,278-92,300,562 ND ND 
HTR7 92,500,576-92,617,671 ND ND 
RPP30 92,631,474-92,668,312 0.05 0.99 
ANKRD1 92,671,857-92,681,032 -1.52 0.01 
XLOC 008559 92,707,057-92,751,889 ND ND 
LOC105378430 92,792,923-92,801,012 ND ND 
LINC00502 92,805,565-92,821,916 ND ND 
NUDT9P1 92,911,761-92,912,837 -0.06 0.99 
PCGF5 92,922,769-93,044,088 0.003 0.99 
HECTD2-AS1 93,066,719-93,371,217 2.84 0.85 
HECTD2 93,170,096-93,274,520 0.28 0.96 
PPP1R3C 93,388,197-93,392,858 0.28 0.86 
TNKS2-AS1 93,542,596-93,558,048 ND ND 
TNKS2 93,558,151-93,625,232 0.25 0.96 
FGFBP3 93,666,345-93,669,258 0.65 0.40 
BTAF1 93,683,736-93,790,080 -0.06 0.99 
a Row shading indicates differentially regulated genes with a q-value < 0.05.  
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TABLE 3.2 
Genes +/- 1Mb of GRE deletion on chromosome 10 whose drug effects are different in the presence of 
mutation. 
Gene Coordinates log2Fold Change q-value 
LOC101926942 92,162,278-92,300,562 ND ND 
HTR7 92,500,576-92,617,671 2.1 1 
RPP30 92,631,474-92,668,312 -0.03 1 
ANKRD1 92,671,857-92,681,032 2 7.39E-10 
XLOC 008559 92,707,057-92,751,889 -0.6 1 
LOC105378430 92,792,923-92,801,012 ND ND 
LINC00502 92,805,565-92,821,916 ND ND 
NUDT9P1 92,911,761-92,912,837 1.5 1 
PCGF5 92,922,769-93,044,088 0.38 1 
HECTD2-AS1 93,066,719-93,371,217 -2.95 1 
HECTD2 93,170,096-93,274,520 -0.21 1 
PPP1R3C 93,388,197-93,392,858 1 1 
TNKS2-AS1 93,542,596-93,558,048 0.89 1 
TNKS2 93,558,151-93,625,232 0.26 1 
FGFBP3 93,666,345-93,669,258 0.08 1 
BTAF1 93,683,736-93,790,080 0.34 1 
a Row shading indicates differentially regulated genes with a q-value < 0.05. 
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TABLE 3.3 
Candidate genes whose expression is primarily affected by GRE deletion. 
Gene Coordinates log2Fold Change q-value 
GPR153 
Chr1: 6,247,346 - 
6,260,990  2.30 0.02 
ETNK2 
Chr1: 204,131,061 - 
204,152,182 1.80 0.01 
ZBTB18 
Chr1: 244,048,939 - 
244,057,476 -1.13 0.03 
ANKRD1 
Chr10: 90,912,096 - 
90,921,276 -2.01 0.19 
SALL1 
Chr16: 51,135,975 - 
51,152,316  1.84 0.02 
Differentially regulated genes with a q-value < 0.2. 
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